ALBUMIN NOVONORDISK 20% Infusion

What is ALBUMIN NOVONORDISK 20%

ALBUMIN NOVONORDISK 20% is a sterile, hyperoncotic (20% w/v) solution of human albumin derived from pooled human plasma, provided in a 100 mL single-use vial for intravenous infusion.

• Pharmaceutical Class: Colloid volume expander (plasma protein solution).
• Primary Indications:
  • Hypovolemia or circulatory shock from trauma, surgery, or hemorrhage.
  • Hypoalbuminemia—when low plasma albumin (<2.5 g/dL) coexists with edema or volume depletion.
  • After large-volume paracentesis in cirrhotic patients to prevent circulatory dysfunction.
  • Burn patients (after initial crystalloid resuscitation).
  • ARDS, nephrotic syndrome, cardiopulmonary bypass priming fluids.
  • Ovarian hyperstimulation syndrome (OHSS).
  • Hemolytic disease of the newborn (HDN) to bind bilirubin.
• Characteristics: Passage through viral inactivation via pasteurization; sterile, non-pyrogenic; single-use.
• Administration Setting: Inpatient use under strict medical monitoring.

Its hyperoncotic nature allows efficient restoration of intravascular volume and supports maintenance of cardiac output and tissue perfusion.

How to use ALBUMIN NOVONORDISK 20%

ALBUMIN NOVONORDISK 20% should be administered intravenously using aseptic technique. Inspect the vial before use—solution must be clear to slightly opalescent, without particulates or discoloration. Warm to room temperature if infusing a large volume.

• Preparation:
  • Do not freeze.
  • Use supplied infusion set; do not mix with other IV fluids unless compatibility verified.
• Infusion:
  • Typical infusion rate: 1–2 mL/min (≈1–2 g albumin/min) :contentReference[oaicite:1]{index=1}.
  • In emergency hypovolemia, may start faster but with close monitoring.
• Monitoring Parameters:
  • Vital signs—BP, HR, respiratory rate, temperature
  • Fluid balance (input/output)
  • Urine output and central venous pressure where applicable
  • Signs of fluid overload—edema, difficulty breathing
• Post-infusion: Discard any unused portion; single-use only.

Dosage adjustments and infusion rates should be individualized based on clinical response, lab results, and patient’s cardiovascular reserve.

Mode of Action ALBUMIN NOVONORDISK 20%

Albumin, a major plasma protein synthesized in the liver, is crucial for maintaining intravascular oncotic pressure and serves as a carrier molecule. Exogenously administered 20% albumin is hyperoncotic, pulling fluid from interstitial and third spaces into blood vessels.

• Oncotic Pressure: Raises plasma colloid osmotic pressure, effectively drawing extracellular fluids into circulation.
• Volume Expansion: Each mL infused may mobilize 2–4 mL of fluid, enhancing preload and improving stroke volume.
• Carrier Function: Binds endogenously produced molecules (bilirubin, fatty acids, hormones) and concurrently administered drugs; helps in detoxifying substances.
• Buffering Capacity: Serves as a weak acid/base buffer, helping stabilize pH.

Albumin provides both therapeutic efficacy in volume resuscitation and physiologic support via molecular transport mechanisms. Its colloid nature is particularly helpful when fluid restriction is needed to avoid edema. :contentReference[oaicite:2]{index=2}

ALBUMIN NOVONORDISK 20% Interactions ALBUMIN NOVONORDISK 20%

As a plasma protein, albumin has minimal direct pharmacologic interactions. However, consider the following:

• Displacement Effects: Large albumin infusions may displace certain drugs (e.g., warfarin, phenytoin, diazepam), increasing free drug fractions :contentReference[oaicite:3]{index=3}.
• ACE‑inhibitors: Combined use may cause hypotension—monitor blood pressure.
• Other Colloids: Concurrent infusion with synthetic colloids (starches, dextrans) may increase intravascular volume—monitor carefully.
• Electrolyte Shifts: Rapid volume expansion can dilute sodium, potassium, calcium—monitor serum electrolytes.

Also note incompatibilities: Do not dilute albumin with sterile water (risk of hemolysis); avoid mixing with protein hydrolysates or alcohol-based solutions. :contentReference[oaicite:4]{index=4}

Dosage of ALBUMIN NOVONORDISK 20%

Dosing is individualized according to patient weight, clinical condition, and response. Daily doses should not exceed 2 g/kg.

• Hypovolemia/Shock:
  • Adults: 25 g IV initially (≈125 mL); repeat in 15–30 min if needed :contentReference[oaicite:5]{index=5}.
  • Children: 0.5–1 g/kg, may repeat :contentReference[oaicite:6]{index=6}.
• Hypoalbuminemia:
  • Adults: 50–75 g/day :contentReference[oaicite:7]{index=7}.
  • Children: ~25 g/day :contentReference[oaicite:8]{index=8}.
• Large-Volume Paracentesis:
  • 8 g per 1 000 mL ascitic fluid removed :contentReference[oaicite:9]{index=9}.
• ARDS: 25 g IV over 30 min, repeat q8h for up to 3 days :contentReference[oaicite:10]{index=10}.
• OHSS: 50–100 g over 4 h, may repeat q4–12h :contentReference[oaicite:11]{index=11}.
• HDN: 1 g/kg before/during exchange transfusion :contentReference[oaicite:12]{index=12}.

Always base dosing adjustments on clinical parameters—vital signs, urine output—not just plasma albumin levels. :contentReference[oaicite:13]{index=13}

Possible side effects of ALBUMIN NOVONORDISK 20%

Human albumin is generally well tolerated, but infusion may cause mild to serious reactions:

• Mild infusional reactions: Fever, chills, flushing, nausea, vomiting, headache; typically temporary and rate-related :contentReference[oaicite:14]{index=14}.
• Cardiovascular effects: Hypotension (especially if infused too quickly or combined with ACE inhibitors), tachycardia :contentReference[oaicite:15]{index=15}.
• Volume overload: Edema, pulmonary congestion, particularly in heart or renal failure patients :contentReference[oaicite:16]{index=16}.
• Allergic/anaphylaxis (rare): Urticaria, bronchospasm, hypotension, potential anaphylactic shock :contentReference[oaicite:17]{index=17}.
• Hemodilution: May dilute hematocrit—monitor and replace cells if needed :contentReference[oaicite:18]{index=18}.

Monitor hemodynamics and labs during infusion. Slow or stop infusion at first sign of adverse reaction.

ALBUMIN NOVONORDISK 20% Contraindications ALBUMIN NOVONORDISK 20%

Certain conditions require absolute or relative contraindications:

• Absolute:
  • Known hypersensitivity to albumin or formulation components.
  • Severe anemia (risk of further hematocrit dilution) :contentReference[oaicite:19]{index=19}.
  • Decompensated heart failure or pulmonary edema—excess volume may worsen condition :contentReference[oaicite:20]{index=20}.
• Relative (use with caution):
  • Renal impairment (risk of volume overload)
  • Uncontrolled hypertension
  • Bleeding disorders
  • Dehydration without true hypovolemia—crystalloids first :contentReference[oaicite:21]{index=21}.
  • Pregnancy/lactation—use only if clearly needed :contentReference[oaicite:22]{index=22}.
  • Pediatric patients—careful dosing and monitoring :contentReference[oaicite:23]{index=23}.

Evaluate contraindications before therapy; monitor high-risk patients closely throughout infusion.

Storage of ALBUMIN NOVONORDISK 20%

Correct storage is vital for maintaining albumin solution integrity and safety:

• Temperature: Store between 2–25 °C (36–77 °F); do not freeze or expose to high heat.
• Light Protection: Keep in original carton to shield from direct light.
• Physical Stability: Avoid shaking to prevent protein denaturation and foaming.
• Before Use:
  • Visually inspect for turbidity or particulates—discard abnormal vials.
  • If large volumes are needed, allow warming to room temperature before infusion.
• Post-Access: Use immediately; discard any remaining solution after opening vial (single-use).
• Disposal: Dispose in compliance with biomedical waste regulations. Do not flush or discard in non-medical trash.

Ensure secure, child-proof storage in healthcare facilities or clinical settings.